18F-FDG PET/CT诊断肾脏病合并肿瘤

目的 评价¹⁸F-FDG PET/CT诊断肾脏病合并肿瘤的应用价值。方法 回顾性分析146例肾脏病患者的¹⁸F-FDG PET/CT表现，检测病灶最大标准摄取值（SUV_max）；以病理学结果作为诊断金标准，计算¹⁸F-FDG PET/CT对肾脏病合并肿瘤的诊断效能。结果 146例肾脏病患者中，29例并发恶性肿瘤，其中肿瘤继发肾损害19例、肾损害伴发肿瘤10例。PET/CT发现72例存在¹⁸F-FDG高摄取灶，病灶SUV_max为5.25±3.94；诊断肿瘤34例，最终确诊29例、误诊5例，诊断灵敏度100%（29/29），特异度88.37%（38/43）。肿瘤继发肾损害病灶SUV_max为5.95±3.02，肾损害伴发肿瘤病灶SUV_max为6.58±5.29，差异无统计学意义（P>0.05）。结论 ¹⁸F-FDG PET/CT可用于筛查肾脏病患者是否合并肿瘤，但对于肿瘤与肾损害关系的诊断价值有限。

18F-FDG PET/CT in diagnosis of renal disease combined with tumor

Objective To explore the value of ¹⁸F-FDG PET/CT in diagnosing renal disease combined with tumor. Methods ¹⁸F-FDG PET/CT data of 146 patients with renal disease were retrospectively analyzed. The maximum standardized uptake value (SUV_max) was measured. The results of pathology were taken as the final diagnostic criteria to evaluate the efficacy of ¹⁸F-FDG PET/CT in diagnosing tumor in patients with renal disease. Results Totally 29 cases were found combined with tumor, including 19 cases with renal damage secondary to tumors and 10 cases as nephropathy coincident with tumors. PET/CT found 72 cases of ¹⁸F-FDG uptake increased (SUV_max=5.25±3.94). ¹⁸F-FDG PET/CT diagnosed tumors in 34 cases, including 29 cases were then confirmed and 5 misdiagnosed, the diagnostic sensitivity and specificity of PET/CT was 100% (29/29) and 88.37% (38/43), respectively. SUV_max of lesions of secondary nephropathy by tumor was 5.95±3.02, SUV_max of lesions of nephropathy coincident with tumor was 6.58±5.29, there was no significant difference (P>0.05). Conclusion ¹⁸F-FDG PET/CT may be used to screen tumors in patients with renal disease, but it has limited value to explore the relationship between renal disease and tumor.